Bluejay Therapeutics

About Bluejay Therapeutics

Bluejay Therapeutics is dedicated to advancing liver science and shifting the treatment paradigm for viral hepatitis and other serious liver diseases. Their mission is to develop innovative therapies to improve the lives of patients impacted by these conditions worldwide, with a team of world-class experts in infectious and liver diseases.

Products & Services

Brelovitug (BJT-778):A therapeutic being evaluated in clinical trials (e.g., AZURE-1 and AZURE-2) for the treatment of Chronic Hepatitis D, compared to existing treatments like Hepcludex (Bulevirtide).

BJT-188:A liver-targeted Fatty Acid Synthase (FASN) inhibitor under investigation in preclinical studies for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Specialties

Viral Hepatitis Treatment Liver Disease Therapeutics Chronic Hepatitis D (CHD) Chronic Hepatitis B (CHB) Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 182000000 MR: - FA: $182 million FAN: 182000000	D: 2024-05-09 FD: 2024-05-09	11 investors

Series C Latest

2024-05-09

$182.0M

11 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Keting Chu

FOUNDER, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD

H

Hassan Javanbakht

Chief Scientific Officer

N

Nancy Shulman

Chief Medical Officer

M

Melissa Koomey

Chief Commercial Officer

M

Mary Cromwell

SVP, Head of Technical Operations

J

Jordan Feld

Professor

View 19 more team members with Pro

Unlock Full Team Directory

Recent News